

**Summit Corporation plc**  
**(“Summit” or “the Company”)**

**SUMMIT IS THE NEW NAME FOR VASTOX**

**New Corporate Website Launched**

**Oxford, UK, 20 July 2007** – Summit Corporation plc (AIM: SUMM), a leading UK biotechnology company, announces that the Company’s name change from VASTox plc (AIM: VOX) has been completed. In parallel with this name change, the Company has launched its new corporate website: [www.summitplc.com](http://www.summitplc.com)

The Company decided to change its name from VASTox to Summit following a period of growth and development that saw it both enhance its drug pipeline and strengthen its core technology capabilities internally and through its recent acquisitions. The new name aims to encapsulate the ambitions of the Company and to provide an identity that has the flexibility to accommodate the future growth and development of the business. The change of name was approved by shareholders at the Company’s AGM on 19 July 2007.

As part of the changes, Summit’s most advanced clinical and preclinical drug candidates will now be known by the following names:

Programme	Status	Former Identity	Summit plc Identity
Parkinson’s: Sialorrhoea	Phase I	DL06001	SMT D001
Parkinson’s: Seborrhoea	Phase I	DL06003	SMT D002
Duchenne muscular dystrophy	Preclinical	VOXC 1100	SMT C1100
VOX 14400	Preclinical	VOX 14400	SMT 14400
Glaucoma	Preclinical	DL06005	SMT D003

Steven Lee, PhD, CEO of Summit plc said: “I am delighted with the support the Company has received from our shareholders that has enabled the Company to change its identity to Summit. I am confident that the Company’s new identity provides the business with a mature identity that will support the future success of our operations.”

- ends -

**For more information please contact:**

**Summit plc**

Steven Lee, PhD, Chief Executive Officer  
Darren Millington, ACMA, Chief Financial Officer

Tel: +44 (0)1235 443951

**Citigate Dewe Rogerson**

Mark Swallow / David Dible / Valerie Auffray

Tel: +44 (0)207 638 9571

**Evolution Securities**

Tim Worledge / Bobbie Hilliam / Neil Elliot

Tel: +44 (0)207 071 4300

**About Summit plc**

Summit plc is a leading UK biotechnology company that discovers and develops proprietary new drugs. The Company's internal drug development programmes are underpinned by its advanced carbohydrate chemistry and drug screening (chemical genomics) technology platforms, which it also provides on a collaborative or fee-for-service basis to the pharmaceutical industry.

Summit plc has a broad range of drug discovery programmes in the clinical, pre-clinical and discovery stages of development, which target serious diseases with a high unmet medical need. These therapeutic areas include neuro-disorders (neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases, oncology and regenerative medicines.

Summit plc's in-house drug development capabilities combine world-class expertise in both carbohydrate chemistry with high-volume, high-content screening using its proprietary zebrafish and fruitfly technologies (chemical genomics). These whole organism screens have the potential to dramatically decrease the time and cost of drug discovery and development by delivering data that are highly predictive of the efficacy and toxicity of potential drug compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October 2004 – symbol: SUMM

Further information about the company is available at [www.summitplc.com](http://www.summitplc.com)

*This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections.*

Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.